shutterstock_1732246315_repelsteeltje
Repelsteeltje / Shutterstock.com
5 February 2021BiotechAlex Baldwin

Pfizer to collaborate with Imcyse on new immunotherapy programme

Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis (RA) using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
16 November 2026   The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
Biotech
13 November 2026   Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.
Biotech
11 November 2026   The parties granted each other the right to use their respective patented inventions in the field of infectious disease but are not obligated to make any payments in connection with the licences.